Sylentis People in the News: Phillip Maples, Catherine Moukheibir Premium Gradalis has promoted Phillip Maples as executive vice president and chief technical officer. Sylentis Preps to Move Glaucoma Drug into Phase II Next Year Premium This article has been updated to correct details regarding SYL1001's development timeline. IP Update: Recent Patents, Patent Applications Awarded to Sylentis, Quark, NIH, and More Premium Title: Inducible Small RNA Expression Constructs for Targeted Gene Silencing Patent Number: 8,198,077 Filed: Jan. 15, 2004 Lead Inventor: Thomas Tuschl, Max Plank Institute Sylentis Picks up Option to Alnylam RNAi IP Premium Alnylam Pharmaceuticals said this week that it has granted Sylentis, a Spanish developer of RNAi drugs, a non-exclusive option to license certain of its RNAi-related intellectual property. Sylentis Authorized to Manufacture Drugs for Research Premium The company said the Spanish Agency for Medicines and Healthcare Products has cleared its lab to make pharmaceutical compounds for research. Sep 9, 2010 Sylentis Cleared to Begin Phase I/II Trial of Ocular Hypertension Drug Premium Jul 8, 2010 Sylentis Concludes Phase Ia Study of Glaucoma Drug Premium Apr 29, 2010 Key RNAi-Based Drugs in the Clinic: April 2010 Premium Apr 1, 2010 Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners Premium Nov 12, 2009 Key RNAi-Based Drugs in the Clinic Premium Aug 20, 2009 Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September Premium Feb 19, 2009 Spain's Sylentis Looks to Move siRNA-Based Glaucoma Drug into Phase I This Year Premium Breaking News 23andMe Stock Soars 22 Percent on Closing of Merger With VG Acquisition Corp IVitalize Acquires Genetic Testing Laboratory Geneus Health GWAS Reveals New Loci Linked to Brain White Matter Microstructure Saga Diagnostics, University College London Cancer Institute Widen Cancer Collaboration New ALS Risk Gene Suggests Role for Apoptosis Weill Cornell Medicine Launches $1.5B Program to Advance Medical Research The Scan Not as High as Hoped The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19. Finding Freshwater DNA A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports. Rise in Payments Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws. Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.